Scroll

nabumetone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
cannabinoid receptors agonists	1863	42924-53-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nabumetone nabucox nabumeton nabuton	A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS. Molecular weight: 228.29 Formula: C15H16O2 CLOGP: 2.98 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 26.30 ALOGS: -5.07 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nabumetone
nabucox
nabumeton
nabuton

A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.

Molecular weight: 228.29
Formula: C15H16O2
CLOGP: 2.98
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 26.30
ALOGS: -5.07
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	35 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	125.15 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 5 of 5 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 24, 1991	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	87.03	13.20	173	10507	310514	63167828
Retinopathy	35.83	13.20	15	10665	3104	63475238
Periarticular disorder	26.21	13.20	5	10675	53	63478289
Rubella	25.87	13.20	6	10674	171	63478171
Off label use	24.37	13.20	48	10632	674414	62803928
Depression	22.99	13.20	79	10601	196413	63281929
Emotional distress	20.00	13.20	26	10654	32523	63445819
Cerebrovascular accident	19.85	13.20	51	10629	107973	63370369
Gastrooesophageal reflux disease	19.52	13.20	47	10633	95592	63382750
Systemic lupus erythematosus	18.58	13.20	6	10674	208912	63269430

Showing 1 to 10 of 18 entries

Previous1 2Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Splenic embolism	50.53	17.75	10	4134	189	34952598
Sideroblastic anaemia	47.90	17.75	10	4134	249	34952538
Vitamin B1 decreased	45.25	17.75	10	4134	328	34952459
Diaphragmatic injury	41.68	17.75	8	4136	128	34952659
Coronary artery disease	34.19	17.75	35	4109	48270	34904517
Implant site infection	33.63	17.75	10	4134	1080	34951707
Marrow hyperplasia	32.99	17.75	10	4134	1153	34951634
Autoimmune haemolytic anaemia	32.31	17.75	14	4130	4482	34948305
Granuloma	29.66	17.75	12	4132	3239	34949548
Granulomatous liver disease	29.64	17.75	8	4136	609	34952178

Showing 1 to 10 of 24 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	94.08	13.68	159	11161	298757	79434311
Splenic embolism	48.10	13.68	10	11310	202	79732866
Sideroblastic anaemia	45.29	13.68	10	11310	271	79732797
Coronary artery disease	45.20	13.68	51	11269	65423	79667645
Diaphragmatic injury	40.24	13.68	8	11312	128	79732940
Retinopathy	38.42	13.68	16	11304	3875	79729193
Vitamin B1 decreased	38.38	13.68	10	11310	553	79732515
Depression	35.38	13.68	88	11232	216702	79516366
Off label use	33.70	13.68	48	11272	907167	78825901
Marrow hyperplasia	27.79	13.68	10	11310	1638	79731430

Showing 1 to 10 of 37 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	M01AX01	MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Other antiinflammatory and antirheumatic agents, non-steroids
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory agent
CHEBI has role	CHEBI:50266	Prodrugs
CHEBI has role	CHEBI:50629	COX-2 inhibitor
FDA CS	M0001335	Anti-Inflammatory Agents, Non-Steroidal
FDA EPC	N0000175722	Nonsteroidal Anti-inflammatory Drug
FDA MoA	N0000000160	Cyclooxygenase Inhibitors
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000893	Anti-Inflammatory Agents

Showing 1 to 10 of 17 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Rheumatoid arthritis	indication	69896004	DOID:7148
Osteoarthritis	indication	396275006
Ankylosing spondylitis	off-label use	9631008	DOID:7147
Juvenile rheumatoid arthritis	off-label use	410795001
Alcoholism	contraindication	7200002
Peptic ulcer	contraindication	13200003	DOID:750
Acute gastric ulcer with perforation	contraindication	19850005
Myocardial infarction	contraindication	22298006	DOID:5844
Hypertensive disorder	contraindication	38341003	DOID:10763
Gastrointestinal ulcer	contraindication	40845000

Showing 1 to 10 of 20 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN		IC50	3.34	WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.73	DRUG MATRIX
Cytochrome P450 1A2	Enzyme	P05177	CP1A2_HUMAN		IC50	5.30	DRUG MATRIX
Amine oxidase [flavin-containing] A	Enzyme	P21397	AOFA_HUMAN		IC50	6.00	DRUG MATRIX

Showing 1 to 5 of 5 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
NBO	PDB_CHEM_ID
003622	NDDF
108508000	SNOMEDCT_US
31448	RXNORM
386859000	SNOMEDCT_US
4020284	VUID
4020284	VANDF
41877	MMSL
4409	PUBCHEM_CID
4855	INN_ID

Showing 1 to 10 of 21 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1657	TABLET, FILM COATED	500 mg	ORAL	ANDA	28 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1658	TABLET, FILM COATED	750 mg	ORAL	ANDA	28 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0145	TABLET	500 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0146	TABLET	750 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0440-5843	TABLET, FILM COATED	500 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0440-5844	TABLET, FILM COATED	750 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3670	TABLET, FILM COATED	500 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3670	TABLET, FILM COATED	500 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3671	TABLET, FILM COATED	750 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3671	TABLET, FILM COATED	750 mg	ORAL	ANDA	26 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next